Skip to main content
. 2012 Feb;26(2):110–118. doi: 10.1089/end.2011.0380

Table 5.

Reasons for the Decline in Renacidin Therapy

Cost
Intense irrigation protocols
Narrow clinical stone population
Advanced monitoring equipment
Advent of minimally invasive therapies
Patient noncompliance and disinterest
Additional ureteral and nephrostomy tubes
Prolonged immobility and hospitalizations
Repeated fluoroscopy to verify effectiveness